Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

ABSTRACT: To evaluate the safety and tolerability of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers. Patients will be followed long-term for Overall Survival (OS) and safety. The study will enroll approximately 90 patients and maximum study treatment duration is approximately 2.13 years.

DISEASE(S): Ovarian Cancer,Leukemia, Myeloid,Triple Negative Breast Neoplasms,Colorectal Cancer,Small Cell Lung Carcinoma,Triple-negative Breast Cancer,Small-cell Lung Cancer,Leukemia, Myeloid, Acute,Acute Myelogenous Leukemia

PROVIDER: 2291112 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR